Guideline History

History of updates

Sort and Filter

  • Sort By title
  • Sort By date
  • Submit
  • Reset

24/05/2024

Perinatal mental health

C24.76-1-V1-R29

  • First publication of consumer information to accompany the Perinatal mental health clinical guideline

23/05/2024

Neonatal medicine monograph Sildenafil

NMedQ24.115-V1-R29

  • First publication of neonatal medicine sildenafil

19/04/2024

Consumer information: Instrumental vaginal birth

C24.49-1-V5-R29

  • Following full review

19/04/2024

Education presentation: Instrumental vaginal birth

E24.49-1-V3-R29

  • Following full review

19/04/2024

Guideline and supplement: Instrumental vaginal birth

MN24.49-V3-R29

  • Following full review

19/04/2024

Education presentation: Preconception and prenatal genetic screening

E24.36-1-V1-R29

  • First publication

19/04/2024

Flowchart Preconception reproductive genetic carrier screening

F24.36-1-V1-R29

  • First publication

19/04/2024

Flowchart Reproductive genetic carrier screening during pregnancy

F24.36-2-V1-R29

  • First publication

19/04/2024

Flowchart Chromosome condition screening during pregnancy

F24.36-3-V1-R29

  • First publication

19/04/2024

Guideline and Supplement: Preconception and prenatal genetic screening

MN24.36-V1-R29

  • First publication

19/04/2024

Flowchart: Management of women with Rh D negative blood group (including NIPA)

F23.74-2-V2-R28

  • Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

19/04/2024

Flowchart: Management of women with Rh D negative blood group (excluding NIPA)

F23.74-1-V2-R28

  • Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

19/04/2024

Education presentation Rh D negative women in pregnancy

E23.74-1-V2-R28

  • Amended: - termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

19/04/2024

Guideline and supplement: Rh D negative women in pregnancy

MN23.74-V2-R28

  • Amended: Termination of pregnancy before 10+0 weeks (medical or surgical) no longer identified as a sensitising event requiring Rh D immunoglobulin

04/04/2024

Perinatal mental health

E24.76-1-V1-R29

  • First publication of education presentation to accompany the Perinatal mental health clinical guideline

04/04/2024

Perinatal mental health

F24.76-1-V1-R29

  • First publication of flowchart to accompany the Perinatal mental health clinical guideline

04/04/2024

Perinatal mental health

MN24.76-V1-R29

  • First publication of Perinatal mental health clinical guideline and supplement

04/04/2024

Neonatal medicine monograph hydralazine hydrochloride

NMedQ24.111-V1-R29

  • First publication of neonatal medicine monograph hydralazine hydrochloride

25/03/2024

Neonatal medicine monograph phosphate

NMedQ22.087-V2-R27

  • Deleted: compound oral solution is no longer available and was deleted

25/03/2024

Neonatal medicine monograph vitamin D

NMedQ22.075-V2-R27

  • Amendment: dosage for neonatal deficiency added

25/03/2024

Neonatal medicine monograph phenobarbital

NMedQ21.062-V2-R26

  • Amendment: duration of IV administration (infusion and injection) added

25/03/2024

Neonatal medicine monograph isradipine

NMedQ24.113-V1-R29

  • First publication of the neonatal medicine monograph isradipine

25/03/2024

Neonatal medicine monograph sprionolactone

NMedQ24.112-V1-R29

  • First publication of the neonatal medicine monograph spironolactone

29/02/2024

Working party list for Newborn bloodspot screening

WP24-53-1-V1-R29

  • List of working party members for the Newborn bloodspot screening guideline

29/02/2024

Parent information Perineal care

C23-30-1-V5-R28

  • "Your perineum and having a baby" parent information to accompany the Perineal care clinical guideline

29/02/2024

Parent information Perineal care

C23-30-2-V6-R28

  • "Third and fourth degree tears" parent information to accompany the Perineal care clinical guideline

25/01/2024

Neonatal medicine monograph benzyl-penicillin

NMedQ20.013-V5-R25

  • Added: definition of current gestational age
  • Amended: instructions for dose frequency to clarify frequency alters as baby ages
  • Added: duration of dosage for congenital syphilis

25/01/2024

Neonatal medicine monograph albumin

NMedQ20.048-V2-R25

  • Amendment: added albumin 5% for Australian transition from 4% to 5% albumin
  • Updated: albumen 20% product name and storage conditions

25/01/2024

Neonatal medicine monograph morphine sulfate

NMedQ20.032-V2-R25

  • Amendment: Added to special considerations: "If prescribed as premedication for elective intubation, wait at least 5 minutes (5–15 minutes) for onset of action before administration of subsequent medications"
  • Removed: UAC icon and amended instructions for administration via UAC

22/12/2023

Term prelabour rupture of membranes (PROM-Term)

C23.47-1-V2-R28

  • Publication of consumer information to accompany the peer review of guideline and supplement

22/12/2023

Term prelabour rupture of membranes (PROM-Term)

E23.47-1-V3-R28

  • Publication of education to accompany the peer review of guideline and supplement

22/12/2023

Term prelabour rupture of membranes (PROM-Term)

MN23.47-V2-R28

  • Publication of of guideline and supplement following peer review

22/12/2023

Preterm prelabour rupture of membranes (PPROM)

MN23.48-V3-R28

  • Publication of guideline and supplement following peer review

22/12/2023

Preterm prelabour rupture of membranes (PPROM)

E23.48-V3-R28

  • Publication of education to accompany the peer review of guideline and supplement

22/12/2023

Preterm prelabour rupture of membranes (PPROM)

C23.48-1-V3-R28

  • Publication of consumer information to accompany the peer review of guideline and supplement

22/12/2023

Perineal care

MN23.30-V5-R28

  • Publication of guideline and supplement following peer review

22/12/2023

Perineal care

E23.30-1-V4-R28

  • Publication of education to accompany the peer review of the perineal care clinical guideline

22/12/2023

Neonatal medicine monograph Indometacin

NMedQ23.104-V1-R28

  • First publication of the neonatal medicine Indometacin

11/12/2023

Neonatal medicine monograph Glucose gel

NMedQ19.020-V2-R24

  • Amendment: Added indication and dose for prophylactic use and a quick guide for dose by weight calculation

30/11/2023

Stabilisation for retrieval-neonatal

E23.18-1-V6-R28

  • Publication: Education presentation to accompany stabilisation for retrieval clinical guideline and supplement

30/11/2023

Stabilisation for retrieval-neonatal

C23.8-1-V5-R28

  • Publication: Consumer information to accompany stabilisation for retrieval clinical guideline and supplement

30/11/2023

Stabilisation for retrieval-neonatal

MN23.18-V5-R28

  • Publication: Peer review of guideline and supplement

30/11/2023

Hypoglycaemia - newborn

C23.8-1-V5-R28

  • Publication: Consumer information to accompany the hypoglycaemia -newborn clinical guideline

30/11/2023

Hypoglycaemia - newborn

E23.8-1-V6-R28

  • Publication: Education presentation to accompany the full review of the hypoglycaemia -newborn clinical guideline

30/11/2023

Hypoglycaemia - newborn

MN23.8-V13-R28

  • Published: Full review of clinical guideline and supplement

07/11/2023

Stillbirth care

MN23.24-V10-R28

  • Amendment: Updated reference to QLD Maternal and Perinatal Quality Council report
  • Amendment: Updated reference to Hospital and Health Services Act

06/10/2023

Termination of pregnancy

Ed19.21-1-V6-R24

  • Amendment: Updated to align with guideline MN19.21-V9-24. Minor wording about capacity to consent

06/10/2023

Termination of pregnancy

F19.21-2-V5-R24

  • Amendment: Updated to align with guideline MN19.21-V9-24. Requirement for prescriber education for MS-2 Step removed

06/10/2023

Termination of pregnancy

MN19.21-V9-R24

  • Amendment: Removed requirements for MS-2 Step prescriber education as per TGA
  • Amendment: Section 5.4 Fetal considerations - new section (section 5.4.3 Born with signs of life) inserted
  • Amendment: Section 5.3 MToP and SToP risks and complications - Live birth added

29/09/2023

Stillbirth care

E23.24-1-V8-R28

  • Publication of education presentation to accompany the Stillbirth care guideline

29/09/2023

Stillbirth care

C23.24-2-V7-R28

  • Publication of consumer information 'Autopsy examination of a baby' to accompany the Stillbirth care guideline

29/09/2023

Stillbirth care

C23.24-1-V7-R28

  • Publication of consumer information 'What to expect after the loss of your baby' to accompany the Stillbirth care guideline

29/09/2023

Stillbirth care

C23.24-3-V3-R28

  • Publication of consumer information 'Grief after your baby dies' to accompany the Stillbirth care guideline

29/09/2023

Stillbirth care

MN23.24-V9-R28

  • Publication of Stillbirth care clinical guideline and supplement following Peer Review

22/09/2023

Neonatal medicine miconazole

NMedQ23.107-V1-R28

  • First publication of neonatal medicine miconazole

22/09/2023

Neonatal medicine glycerol

NMedQ23.108-V1-R28

  • First publication of neonatal medicine glycerol

22/09/2023

Neonatal medicine microlax

NMedQ23.103-V1-R28

  • First publication of neonatal medicine microlax

22/09/2023

Neonatal medicine nystatin

NMedQ23.100-V1-R28

  • First publication of neonatal medicine nystatin

18/09/2023

Instrumental vaginal birth

MN18.49-V2-R23

  • Review date extended until Dec 2024. No change to content

18/09/2023

Perineal care

MN18.30-V4-R23

  • Review date extended until Dec 2024. No change to content

18/09/2023

Primary postpartum haemorrhage

MN18.1-V10-R23

  • Review date extended until Dec 2024. No change to content

18/09/2023

Syphilis in pregnancy

MN18.44-V6-R23

  • Review date extended until Dec 2024. No change to content

25/08/2023

Syphilis in pregnancy

MN18.44-V6-R23

  • Amendment: To align with QMPQC recommendations for routine antenatal screening at 36 weeks

31/07/2023

Fetal movements

MN23.46-V3-R28

  • Peer review
  • Formatting and references updated

18/07/2023

Normal birth

MN22.25-V5-R27

  • Amendments to Section 2.1 Continuity of care: Statistical analysis in Tables 4 and 5 amended from Absolute Risk Reduction/Absolute Benefit Increase to;Risk Ratio.

22/06/2023

Induction of labour

MN22-22-V9-R27

  • Update: Statistics in Table 5, Table 6, Table 13 and Table 23 updated
  • Addition to Flowchart: Oxytocin and Appendix D: Oxytocin regimen administration: Caution note and suggested maximum oxytocin dosage for use in women with previous uterine surgery added

15/06/2023

Establishing breastfeeding

MN21-19-V5-R26

  • Amendment: Section 6. Recommended time frame to express breasts if baby unable to initiate breastfeeding or is separated from mother-changed from within six hours of birth, to within two hours of birth
  • Amendment: Appendix D: Breast engorgement and mastitis spectrum sections updated

15/6/2023

Neonatal medicine dexmedetomidine

NMedQ23.101-V1-R28

  • First publication of neonatal medicine dexmedetomidine

15/6/2023

Neonatal medicine trimethoprim with sulfamethoxazole

NMedQ23.106-V1-R28

  • First publication of neonatal medicine trimethoprim with sulfamethoxazole

15/6/2023

Neonatal medicine heparin sodium

NMedQ23.102-V1-R28

  • First publication of neonatal medicine heparin sodium

15/6/2023

Neonatal medicine omeprazole

NMedQ23.105-V1-R28

  • First publication of neonatal medicine omeprazole

28/04/2023

Clinical form: Neonatal seizure and neurological observations

SW1209-V1

  • First publication of clinical form for neonatal seizure and neurological observation

28/04/2023

Clinical form: Encephalopathy servity assessment and therapeutic cooling critiera

SW1208-V1

  • First publication of clinical form for encephalopathy severity assessment and therapeutic hypothermia criteria

21/04/2023

Education presentation: Neonatal resuscitation

E22.5-1-V6-R27

  • Amendment to education presentation to clarify chest compression techniques to be used if one or two person performing

21/04/2023

Working party list: Fetal movements

WP23.46-1-V2-R28

  • List of working party members for review of fetal movements

21/04/2023

Education presentation: Rh D woman and pregnancy

E23.74-1-V1-R28

  • New publication education presentation

21/04/2023

Consumer information: Rh D woman and pregnancy

C23.74-1-V1-R28

  • New publication consumer information sheet

31/03/2023

Neonatal medicine benzylpenicillin

NMedQ20.013-V4-R25

  • Amendment to align with ASID recommendations for term infants: Dosage for sepsis (IV and IM) for baby at 37+0 weeks or more current gestational age at 8 or more days of age FROM 60 mg/kg every 8 hours TO 60mg/kg every 6 hours.

31/03/2023

Neonatal medicine clonidine

NMedQ22.085-V2-R27

  • Amendment: Preparation instructions for tablet use added

30/03/2023

Term small for gestational age baby

MN22-16-V6-R27

  • Amendment: Correction Table 9. Estimate of growth restriction using Fenton growth charts - Female weight at 41+0 weeks gestation on 10th percentile FROM 3980 g TO 2980 g

30/03/2023

Retinopathy of prematurity consensus statement

O21.55-1-V2-R26

  • Amendment: Added for further information refer to RANZCO guideline

30/03/2023

List of working party members for Stillbirth care review

WP23.24-1-V1-R28

  • Working party members for Stillbirth care review

30/03/2023

Guideline: Rh D negative women and pregnancy

MN23.74-V1-R28

  • New publication clinical guideline and supplement

10/03/2023

Consumer information: Breastfeeding and medicines

C23.19-2-V1-R28

  • New publication to accompany breastfeeding clinical guideline

10/03/2023

Consumer information: Induction of labour (IOL)

C23.22-1-V4-R27

  • Accompany IOL clinical guideline

10/03/2023

Consumer information: Induction of labour (IOL): Part 1 cervical ripening

C23.22-2-V1-R27

  • New publication to accompany IOL clinical guideline

10/03/2023

Consumer information: Induction of labour (IOL): Part 2 rupturing your membranes and oxytocin

C23.22-3-V1-R27

  • New publication to accompany IOL clinical guideline

28/02/2023

Guideline: Intrapartum pain management

MN23.75-V1-R28

  • First publication of clinical guideline on intrapartum pain management and associated resources
  • Incorporated existing 4 shortGuides on pharmacological analgesia (now rescinded)

28/02/2023

Neonatal medicine poloxamer 10%

NMedQ23.099-V1-R28

  • First publication of neonatal medicine poloxamer 10%

28/02/2023

Neonatal medicine palivizumab

NMedQ23.098-V1-R28

  • First publication of neonatal medicine palivizumab

28/02/2023

Neonatal medicine rasburicase

NMedQ23.097-V1-R28

  • First publication of neonatal medicine rasburicase

28/02/2023

Neonatal medicine levothyroxine

NMedQ23.096-V1-R28

  • First publication of neonatal medicine levothyroxine

15/02/2023

Guideline Stillbirth care

MN18.24-V8-R23

  • Review date extended while review in progress. Nil other amendments

15/02/2023

Guideline Neonatal stabilisation for retrieval

MN18.18-V4-R23

  • Review date extended while review in progress. Nil other amendments

06/02/2023

Eduction presentation Gestational diabetes mellitus

E21.33-1-V3-R26

  • Amendment slide 23 Metformin: Maximum dose metformin: FROM 2500 mg standard release (SR) TO: Metformin 2500 mg intermediate release (IR)

06/02/2023

Neonatal medicine Adrenaline

NMedQ22.079-V4-R27

  • Amendment: Added to ETT dose: volume equivalent in mL/kg

06/02/2023

Neonatal medicine Caffeine Citrate

NMedQ19.006-V2-R24

  • Added to preparation instructions: prescribed dose greater than 0.5 mL (10 mg) may be given undiluted
  • Added to special considerations: small dose volumes can be difficult to administer accurately to VLBW infants therefore diluted preparation is the preferred option in this cohort
  • Added to signs of toxicity: tremors and tachypnoea
  • Added QR code
  • Deleted UAC icon: wording amended about administration via UAC
  • Minor referencing updates

16/01/2023

Neonatal medicine Vancomycin

NMedQ23.094-V1-R28

  • First publication of neonatal medicine vancomycin

16/01/2023

Neonatal medicine Valganciclovir

NMedQ23.093-V1-R28

  • First publication of neonatal medicine valganciclovir

16/01/2023

Neonatal medicine Ganciclovir

NMedQ23.092-V1-R28

  • First publication of neonatal medicine ganciclovir

16/01/2023

Neonatal medicine Fluconazole

NMedQ23.095-V1-R28

  • First publication of neonatal medicine fluconazole

03/01/2023

Neonatal medicine Adrenaline

NMedQ22.079-V3-R27

  • Amendment: Correction to IV infusion preparation instructions. FROM: Draw up 0.3 mg/kg (0.3 mL/kg of 1:10,000) TO: Draw up 0.3 mg/kg (3 mL/kg of 1:10,000)s

21/12/2022

Termination of pregnancy

MN19.21-V8-R24

  • Amendment: For MS-2 Step: FROM undertake routine antenatal serum screening. TO: If MToP with MS-2 Step, routine antenatal serum screening not required, consider based on history/opportunistically with other serum tests

21/12/2022

Neonatal jaundice

MN22.7-V9-R27

  • Full Review
  • Removed: Elements of care relevant to QCG 'Standard care' clinical guideline
  • Removed: Nomograms referenced to QCG 'Nomograms for jaundice phototherapy and exchange transfusion'

21/12/2022

Neonatal seizures

MN22.23-V4-R27

  • Full Review
  • Removed: Elements of care relevant to QCG 'Standard care' clinical guideline
  • Removed: Drug regimens referenced to QCG 'NeoMedQ neonatal medicine monographs'
  • Updated: Classification of seizures as per International League of Epilepsy

21/12/2022

Induction of labour

MN22.22-V8-R27

  • Full Review
  • Expanded: Guidance on communication and decision making, timing of birth, risks and benefits of IOL compared with expectant management, setting for cervical ripening
  • Updated: prolonged pregnancy, suspected fetal macrosomia, intrahepatic cholestasis, advanced maternal age, transcervical balloon catheter

21/12/2022

Normal birth

MN22.25-V4-R27

  • Full Review
  • Removed: Elements of care relevant to 'Standard care' clinical guideline
  • Transferred to 'Intrapartum pain management' clinical guideline: Pharmacological and non pharmacological support including water immersion, and nitrous oxide and oxygen

05/12/2022

Preterm labour and birth

MN20.06-V10-R25

  • Flowchart MgSO4: Amendment - loading dose aligned with text FROM over 15 minutes | TO over 20 minutes
  • Table 2. Risk factors associated with preterm birth: Addition - risk of PTB based on ethnicity
  • Table 3 Risk reduction measures: Addition - recommendation for universal routine cervical length measurement during mid-trimester ultrasound
  • Section 3.1 Progesterone therapy: Amendment - recommendation strengthened FROM Consider prophylactic progesterone | TO Recommend vaginal progesterone from 16-36 weeks if incidentally diagnosed shortened cervix or prior spontaneous preterm birth between 20–34 weeks
  • Section 3.2 Cervical cerclage: Addition - consider cervical cerclage for women with cervical length less than 10 mm
  • Section 5.4 Antenatal corticosteroids: Amendment - recommendations aligned with QCG guideline: Antenatal corticosteroids

25/11/2022

Standard care

MN22.50-V2-R27

  • Guideline and supplement (Full Review)

22/11/2022

Pain and bleeding in early pregnancy

C22.29-2-V4-R27

  • New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

22/11/2022

Having a miscarriage

C22.29-4-V1-R27

  • New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

22/11/2022

Ectopic pregnancy

C22.29-1-V2-R27

  • New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

22/11/2022

Methotrexate for ectopic pregnancy

C22.29-5-V1-R27

  • New publication: Consumer information to accompany the Early pregnancy loss clinical guideline

11/11/2022

Neonatal resuscitation checklist

F22.5-3-V3-R27

  • Amendment: Added additional equipment when humidification required (adaptor 15m/10f-10m neonatal; humidification T-piece circuit;humidifer chamber; sterile water for injection 1L bag)

09/11/2022

Hypoxic ischaemic encephalopathy

MN21.11-V11-R26

  • Amendment: Table 6 HIE staging, to align with Flowchart Assessing baby for therapeutic hypothermia FROM: If three or more signs of moderate or severe HIE or seizures at any time in first six hours consult with neonatologist regarding commencing TH. TO: If two or more signs of moderate or severe HIE or seizures at any time in first six hours consult with neonatologist regarding commencing TH

09/11/2022

Termination of pregnancy

MN19.21-V7-R24

  • Amendment: Rh D immunoglobulin no longer recommended for MToP before 10+0 weeks gestation
  • Amendment: Recommendation for prophylactic antibiotics for MToP changed FROM: Insufficient evidence to recommend the use of antibiotics prior to MToP TO: Prophylactic antibiotics not recommended for MToP
  • Added: Information when counselling women about the potential for live birth

28/10/2022

Syphilis in pregnancy

MN18.44-V5-R23

  • Amendment: Universal screening at 28 weeks gestation recommended

14/10/2022

Early pregnancy loss

MN22.29-V6-R27

  • Guideline and associated resources: Peer review

14/10/2022

Neonatal resuscitation

MN22.5-V6-R27

  • Guideline and associated resources: Peer review

26/09/2022

Neonatal medicine pyridoxine

NMedQ22.089-V1-R27

  • First publication neonatal medicine pyridoxine

26/09/2022

Neonatal medicine phenytoin

NMedQ22.090-V1-R27

  • First publication neonatal medicine phenytoin

26/09/2022

Neonatal medicine lidocaine

NMedQ22.091-V1-R27

  • First publication neonatal medicine lidocaine

26/09/2022

Neonatal medicine clonazepam

NMedQ22.088-V1-R27

  • First publication neonatal medicine clonazepam

21/09/2022

Adult inpatient management of steroid induced hyperglycaemia

ACG22.73-1-V1-R27

  • First publication (in collaboration with Queensland Diabetes Clinical Network)

09/08/2022

Early onset Group B Streptococcal disease

MN22.20-V6-R27

  • Flowchart: Neonatal management of early onset Group B Streptococcal disease (EOGBSD) updated to reflect text
  • Section 2 Risk factors: FROM another baby of multiple | TO other baby of multiple
  • Section 5.2 Criteria for investigation of sepsis: increased observation – removal of preterm labour at less than 37+0 weeks
  • Section 5.2 Criteria for investigation of sepsis: increased observation – addition of guidance for monitoring newborn with sibling currently treated for GBS infection
  • Section 5.4 Antibiotic therapy: FROM treatment of GBS meningitis for diagnosed infection | TO guidance for treatment of both confirmed and suspected GBS meningitis

02/08/2022

Aciclovir

NMedQ19.10-V3.R24

  • Amendment to preparation instructions: powdered vial no longer available

29/07/2022

Safer infant sleep

MN22.71-V1-R27

  • First publication (in collaboration with QLD Paediatric Quality Council)

29/07/2022

Early onset Group B Streptococcal disease

MN22.20-V5-R27

  • Peer Review: Risk factor approach re-endorsed

26/07/2022

Neonatal medicine adrenaline (epinephrine)

NMedQ22.079-V2-R27

  • Amendment: to align with ANZCOR recommendation for rapid IV bolus during resuscitation. FROM: Adrenalin every 2–3 minutes TO: Adrenaline every 3–5 minutes

26/07/2022

Neonatal medicine phosphate

NMedQ22.087-V1-R27

  • First publication neonatal medicine phosphate

26/07/2022

Neonatal medicine magnesium sulfate

NMedQ22.086-V1-R27

  • First publication neonatal medicine magnesium sulfate

26/07/2022

Neonatal medicine clonidine

NMedQ22.085-V1-R27

  • First publication neonatal medicine clonidine

26/07/2022

Neonatal medicine azithromycin

NMedQ22.084-V1-R27

  • First publication neonatal medicine azithromycin

26/07/2022

Neonatal medicine argipressin (vasopressin)

NMedQ22.083-V1-R27

  • First publication neonatal medicine argipressin

14/06/2022

Hypoglycaemia - newborn

MN19.8-V12-R24

  • Amendments Flowchart 3: Management of neonatal hypoglycaemia (baby symptomatic or BGL 1.5 mmol/L
    • Renamed TO Management of BGL less than 1.5 mmol/L or baby symptomatic,
    • Amended criteria for commencement of weaning IV therapy to align with document text
      • FROM BGL 2.6 mmol/L for more than 12 hours
      • TO BGL 3.0 mmol/L for more than 12 hours.
    • Duplicate label on outflow amended FROM yes TO no
    • Urgent treatment:
      • FROM If asymptomatic or mild symptoms: Administer IV 10% glucose bolus, Consider glucose gel 40% and breastfeed in addition, Commence 10% glucose infusion at 60 mL/kg, Give glucagon IM or subcut if IV access delayed by more than 15 minutes -If symptomatic or BGL not improving: Give glucagon IV (IM or subcut if IV access delayed by more than 15 minutes), Commence 10% glucose infusion at 80 mL/kg
      • TO Commence 10% glucose infusion at 60 mL/kg/day, If symptomatic or BGL not improving commence at 80 mL/kg/day; Give 10% glucose 1–2 mL/kg IV bolus Consider glucose gel 40% and breastfeed, Recheck BGL after 30 minutes, If BGL improving, continue 10% glucose IV adjust as needed, If symptomatic or BGL not improving give glucagon IV, Repeat BGL after 30 minutes and if required, repeat glucose bolus and glucagon, If IV access delayed > 15 minutes give glucagon IM or subcut.
  • Added to Definitions: enteral feeding
  • Table 5 Screening:
    • Last row split into two rows (new row: Validate BGL less than 2.6 mmol/L) no content change
  • Table 8: Initial management (first 48 hours of life)
    • References to NeoMedQ monographs rationalised to top of page
    • Third row (BGL less than 1.5 mmol/L or unrecordable) spilt into two rows (new row Difficult IV access) no content change
    • Last row: (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring
  • Table 11: BGL monitoring First row (BGL)
    • Split into 5 rows (no content change)
    • Last row (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring
  • Table 12: Ceasing BGL monitoring
    • New table from content in Table 8 and Table 11
    • Correction to criteria for ceasing after 48 hours
      • FROM 3 mmol/L TO 3.3 mmol/L
  • Subsequent table numbering increased by 1
  • Table 15: Medications
    • References updated to relevant NeoMedQ medicine monographs only
  • Minor formatting corrections throughout

19/05/2022

Gestational diabetes mellitus

MN21.33-V7-R26

  • Flowchart: Screening and diagnosis of GDM - amended: information from guideline (Table 16 Self-monitoring) about fasting BGL and commencement of pre- and postprandial self-monitoring (when OGTT not suitable)

19/05/2022

Neonatal medicine topiramate

NMedQ21.067-V2-R26

  • Deleted from special considerations “if therapeutic hypothermia refer to QCG Neonatal seizures guideline”

16/05/2022

Neonatal Seizures

MN17.23-V3-R22

  • Review date extended FROM May 2022 TO May 2023

16/05/2022

Early pregnancy loss

MN17.29-V5-R22

  • Review date extended FROM May 2022 TO May 2023

16/05/2022

Induction of labour

MN17.22-V7-R22

  • Review date extended FROM March 2022 TO March 2023

16/05/2022

Gestational diabetes mellitus

MN21.33-V6-R26

  • Flowchart: Screening and diagnosis of GDM - added: information from guideline (Table 16 Self-monitoring) for suggested target BGLs when self-monitoring
  • Flowchart Screening and diagnosis of GDM and Tables 8 and 14: - FROM: ‘evidence of fetal hyperinsulinaemia on growth USS’. TO: ‘evidence of excess fetal growth/adiposity on growth USS’
  • Table 20 Metformin FROM: Maximum dose: 2500mg (SR) TO: Maximum dose: 2500mg (immediate release) (no dose change)

29/04/2022

Statewide nomograms forms (all)

SW1106 to SW1111 (V2)

  • Update (all): additional fields to capture start and end time of phototherapy

29/04/2022

Maternity care for mothers and babies during the COVID-19 pandemic

MN21.063-V12-R26

  • Guideline, supplement and flowchart: Updated information about close contact management. Update to COVID-19 vaccination intervals after positive COVID-19 result.

21/04/2022

Neonatal medicine vitamin D

NMedQ22.075-V2-R27

  • Added: information if receiving low birth weight formula or human milk fortifier and commencement if no previous pentavite.

21/04/2022

Preterm prelabour rupture of membranes (PPROM)

MN18.48-V2-R23

  • Guideline and education: Recommended antibiotics for PPROM updated and aligned with Therapeutic Guidelines.

25/03/2022

Hypoglycaemia - newborn

MN19.8-V11-R24

  • Guideline and flowchart: Treatment recommendations for symptomatic baby or BSL less than 1.5 mmol/L with glucagon and glucose amended at Section 4.2, Section 4.5.1, and flowchart management of neonatal hypoglycaemia (baby symptomatic or BGL less than 1.5 mmol/L).

25/03/2022

Term small for gestational age newborn baby

MN22.16-V6-R27

  • Guideline and associated resources: Full review

09/03/2022

Termination of pregnancy

MN19.21-V6-R24

  • Guideline: Alignment with legislative amendments related to student health practitioner assisting with a termination
  • Guideline: Alignment with legislative amendments related to child abuse (Criminal Code Act 1899)

09/03/2022

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V11-R26

  • Guideline: Neonatal flowchart updated to include close contact testing and isolation/quarantine requirements
  • Guideline: Visitor restrictions to a neonatal unit specified

01/03/2022

Neonatal medicine metronidazole

NMedQ22.080-V1-R27

  • First publication neonatal medicine metronidazole

01/03/2022

Neonatal medicine micafungin

NMedQ22.081-V1-R27

  • First publication neonatal medicine micafungin

01/03/2022

Neonatal medicine omnipaque

NMedQ22.082-V1-R27

  • First publication neonatal medicine omnipaque

01/03/2022

Neonatal medicine adrenaline

NMedQ22.079-V1-R27

  • First publication neonatal medicine adrenaline

01/03/2022

Rheumatic heart disease and pregnancy

MN22.40-1-V1-R27

  • First publication

16/02/2022

Neonatal medicine ceftriaxone

NeoMedQ21.068-V5-R26

  • Added: Preparation instructions for IM 350 mg/mL final concentration

10/02/2022

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V10-R26

  • Guideline: Definition of a neonatal (baby) close contact amended
  • Guideline: Visitor information updated

11/01/2022

Consumer role

O22.34-4-V3-R27

  • Published Consumer representative role updated

11/01/2022

Neonatal medicine vitamin E

NMedQ22.076-V1-R27

  • First publication neonatal medicine monograph vitamin E

11/01/2022

Neonatal medicine vitamin D

NMedQ22.075-V1-R27

  • First publication neonatal medicine monograph vitamin D

11/01/2022

Neonatal medicine vitalipid N (infant)

NMedQ22.078-V1-R27

  • First publication neonatal medicine monograph vitalipid N (infant)

11/01/2022

Neonatal medicine prednisolone

NMedQ22.074-V1-R27

  • First publication neonatal medicine monograph prednisolone

11/01/2022

Neonatal medicine pentavite

NMedQ22.077-V1-R27

  • First publication neonatal medicine monograph pentavite

07/01/2022

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V9-R26

  • Guideline: removed reference to patient transfer to designated hospital

05/01/2022

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V8-R26

  • Guideline, education presentation and consumer information: Added booster vaccination information, added omicron variant of concern

20/12/2021

Hypoxic ischaemic encephalopathy (HIE)

MN21.11-V10-R26

  • Peer review and update of literature and references

20/12/2021

Maternity shared care operational framework

MN21.27-V3-R26

  • Full review and update of literature and references
  • Elements of Standard care removed

26/11/2021

Newborn assessment (routine)

MN21.4-V6-R26

  • Peer review and update of literature and references
  • Added: additional detail about newborn bloodspot screening
  • Added: flowchart for critical congenital heart disease screening

26/11/2021

Establishing breastfeeding

MN21.19-V4-R26

  • Peer review and update of literature and references

22/11/2021

Maternity care for mothers and babies during COVID-19 pandemic

MN21.63-V7-R26

  • Full review and update of literature and references
  • New: Flowchart Location and precautions if SCOVID or COVID-19, including rapid PCR testing
  • New: Section Peripartum risk management with abbreviated and reordered infection prevention and control information
  • New: Section Clinical course in pregnancy and postpartum
  • New: Recommendations for ACE inhibitors, carboprost, tranexamic acid, low dose aspirin, delayed cord clamping, neonatal testing for COVID-19, neonatal administration of vitamin K, hepatitis B vaccine and immunoglobulin
  • New: Information for neonatal supportive care
  • Updated information: vaccination, organisation of neonatal unit
  • Deleted: Flowchart Assessment of inpatient woman
  • Deleted: Operational Framework

15/11/2021

Neonatal resuscitation

MN16.5-V5-R21

  • Review date extended FROM Nov 2021 TO Dec 2022. Nil content changes

15/11/2021

Early onset Group B streptococcal disease

MN16.20-V4-R21

Last updated: 24 May 2024